A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Adjuvant Lapatinib (GW572016) in Women With Early-Stage ErbB2 Overexpressing Breast Cancer.
Phase of Trial: Phase III
Latest Information Update: 23 Feb 2017
At a glance
- Drugs Lapatinib (Primary)
- Indications Early breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms TEACH
- Sponsors GlaxoSmithKline
- 10 Jun 2017 Biomarkers information updated
- 29 Jan 2016 Subgroup analysis (n=2489) published in the European Journal of Cancer.
- 04 Aug 2014 Last checked against M.D. Anderson Cancer Center record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History